Annual Shareholders Equity
$394.97 M
-$95.18 M-19.42%
December 31, 2023
Summary
- As of February 12, 2025, KYMR annual stockholders equity is $394.97 million, with the most recent change of -$95.18 million (-19.42%) on December 31, 2023.
- During the last 3 years, KYMR annual shareholders equity has risen by +$111.08 million (+39.13%).
- KYMR annual shareholders equity is now -19.42% below its all-time high of $490.15 million, reached on December 31, 2022.
Performance
KYMR Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
$892.93 M
+$208.01 M+30.37%
September 30, 2024
Summary
- As of February 12, 2025, KYMR quarterly stockholders equity is $892.93 million, with the most recent change of +$208.01 million (+30.37%) on September 30, 2024.
- Over the past year, KYMR quarterly shareholders equity has increased by +$497.96 million (+126.07%).
- KYMR quarterly shareholders equity is now at all-time high.
Performance
KYMR Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
KYMR Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -19.4% | +126.1% |
| 3 y3 years | +39.1% | +126.1% |
| 5 y5 years | +1247.0% | +126.1% |
KYMR Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -19.4% | at low | at high | +126.1% |
| 5 y | 5-year | -19.4% | +630.8% | at high | +1300.1% |
| alltime | all time | -19.4% | +630.8% | at high | +1300.1% |
Kymera Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $892.93 M(+30.4%) |
| Jun 2024 | - | $684.92 M(-3.7%) |
| Mar 2024 | - | $711.20 M(+80.1%) |
| Dec 2023 | $394.97 M(-19.4%) | $394.97 M(-0.1%) |
| Sep 2023 | - | $395.54 M(-9.2%) |
| Jun 2023 | - | $435.43 M(-5.8%) |
| Mar 2023 | - | $462.00 M(-5.7%) |
| Dec 2022 | $490.15 M | $490.15 M(-4.4%) |
| Sep 2022 | - | $512.88 M(+28.9%) |
| Jun 2022 | - | $397.95 M(-7.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $428.72 M(-6.7%) |
| Dec 2021 | $459.64 M(+61.9%) | $459.64 M(-4.9%) |
| Sep 2021 | - | $483.13 M(+87.2%) |
| Jun 2021 | - | $258.10 M(-6.2%) |
| Mar 2021 | - | $275.25 M(-3.0%) |
| Dec 2020 | $283.89 M(-481.5%) | $283.89 M(-3.7%) |
| Sep 2020 | - | $294.69 M(+183.2%) |
| Jun 2020 | - | $104.04 M(-239.8%) |
| Dec 2019 | -$74.41 M(+116.1%) | -$74.41 M |
| Dec 2018 | -$34.44 M | - |
FAQ
- What is Kymera Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for Kymera Therapeutics?
- What is Kymera Therapeutics annual shareholders equity year-on-year change?
- What is Kymera Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Kymera Therapeutics?
- What is Kymera Therapeutics quarterly shareholders equity year-on-year change?
What is Kymera Therapeutics annual stockholders equity?
The current annual shareholders equity of KYMR is $394.97 M
What is the all time high annual shareholders equity for Kymera Therapeutics?
Kymera Therapeutics all-time high annual stockholders equity is $490.15 M
What is Kymera Therapeutics annual shareholders equity year-on-year change?
Over the past year, KYMR annual stockholders equity has changed by -$95.18 M (-19.42%)
What is Kymera Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of KYMR is $892.93 M
What is the all time high quarterly shareholders equity for Kymera Therapeutics?
Kymera Therapeutics all-time high quarterly stockholders equity is $892.93 M
What is Kymera Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, KYMR quarterly stockholders equity has changed by +$497.96 M (+126.07%)